Search bioRxiv⌕ Search

Biology subjects

Trebucq, L. L.

Publications and source records attributed to Trebucq, L. L..

2 recordsLinked to original sources

Modern Times: Longitudinal Study of Toba/Qom Communities Reveals Delay and Shortening of Sleep in Real-Time Across Electrification

While artificial light and digital technologies are widely assumed to delay and curtail sleep, direct, longitudinal evidence documenting these changes is remarkably scarce. From 2012 to 2024, we conducted a longitudinal study of native Toba/Qom communities in northern Argentina, including rural groups newly introduced to electricity and semi-urban groups with earlier access to electricity. Using linear mixed-effects models on a dataset of over 12,000 actigraphically recorded sleep events from 156 participants at different times, we observed striking shifts in sleep dynamics. Remarkably, both groups showed delays of up to 1.4 hours in sleep timing, and participants from rural communities lost a full hour of sleep within just a decade. These changes occurred across a period that included, first, the introduction of electricity to rural communities after 2016, and, in more recent years, the spread of the internet and smartphone use among the Toba/Qom. Our models reveal that these events alone cannot fully explain the observed shifts in sleep timing, suggesting that broader processes of modernization and acculturation, beyond electric light and digital devices alone, may be driving sleep changes. The rapid transformations observed in these communities mirror, within a single decade, the likely trajectory of human sleep across the 20th and early 21st centuries, underscoring the complex ways modern environments reshape sleep behavior.

physiology↗

Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma

BackgroundGlioblastoma (GBM) is the most common primary brain tumor in adults. Despite extensive research and clinical trials, median survival post-treatment remains at 15 months. Thus, all opportunities to optimize current treatments and improve patient outcomes should be considered. A recent retrospective clinical study found that taking TMZ in the morning compared to the evening was associated with a 6-month increase in median survival in patients with MGMT-methylated GBM. Here, we hypothesized that TMZ efficacy depends on time-of-day and O6-Methylguanine-DNA Methyltransferase (MGMT) activity in murine and human models of GBM. Methods and ResultsIn vitro recordings using real-time bioluminescence reporters revealed that GBM cells have intrinsic circadian rhythms in the expression of the core circadian clock genes Bmal1 and Per2, as well as in the DNA repair enzyme, MGMT. Independent measures of MGMT transcript levels and promoter methylation also showed daily rhythms intrinsic to GBM cells. These cells were more susceptible to TMZ when delivered at the daily peak of Bmal1 transcription. We found that in vivo morning administration of TMZ also decreased tumor size and increased body weight compared to evening drug delivery in mice bearing GBM xenografts. Finally, inhibition of MGMT activity with O6-Benzylguanine abrogated the daily rhythm in sensitivity to TMZ in vitro by increasing sensitivity at both the peak and trough of Bmal1 expression. ConclusionWe conclude that chemotherapy with TMZ can be dramatically enhanced by delivering at the daily maximum of tumor Bmal1 expression and minimum of MGMT activity. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=164 SRC="FIGDIR/small/557630v1_ufig1.gif" ALT="Figure 1"> View larger version (36K): org.highwire.dtl.DTLVardef@2e9058org.highwire.dtl.DTLVardef@1069917org.highwire.dtl.DTLVardef@2cf000org.highwire.dtl.DTLVardef@40abc9_HPS_FORMAT_FIGEXP M_FIG C_FIG

cancer biology↗